Effectiveness of quality of care for patients with type 2 diabetes in China: findings from the Shanghai Integration Model (SIM)

Abstract

This cross-sectional study aimed to investigate the quality of care of diabetes in Shanghai, China. A total of 173 235 patients with type 2 diabetes in 2017 were included in the analysis. Profiles of risk factors and intermediate outcomes were determined. The patients had a mean age of 66.43±8.12 (standard deviation (SD)) years and a mean diabetes duration of 7.95±5.53 (SD) years. The percentage of patients who achieved the target level for HbA_1c (<7.0%) was 48.6%. Patients who achieved the target levels for blood pressure (BP)<130/80 mmHg and low-density lipoprotein-cholesterol (LDL-c)<2.6 mmol/L reached 17.5% and 34.0%, respectively. A total of 3.8% achieved all three target levels, and the value increased to 6.8% with an adaptation of the BP target level (<140/90 mmHg) for those over 65 years. Multivariable analysis identified the factors associated with a great likelihood of achieving all three target levels: male, young age, short diabetes duration, low body mass index, macrovascular complications, no microvascular complications, prescribed with lipid-lowering medication, and no prescription of antihypertensive medication. In conclusion, nearly 50% and one-third of the patients with diabetes met the target levels for HbA_1c and LDL-c, respectively, with a low percentage achieving the BP target level. The percentage of patients who achieved all three target levels needs significant improvement.

Keywords

type 2 diabetes / quality of care / macrovascular complication / microvascular complication / treatment pattern / epidemiology

References

[1] International Diabetes Federation. IDF Diabetes Atlas, 9th ed. Brussels, Belgium: International Diabetes Federation. 2019. accessed April 26, 2021)

[2] Pan XR, Yang WY, Li GW, Liu J; National Diabetes Prevention and Control Cooperative Group. Prevalence of diabetes and its risk factors in China, 1994. Diabetes Care 1997; 20(11): 1664–1669

[3] Yang W, Lu J, Weng J, Jia W, Ji L, Xiao J, Shan Z, Liu J, Tian H, Ji Q, Zhu D, Ge J, Lin L, Chen L, Guo X, Zhao Z, Li Q, Zhou Z, Shan G, He J; China National Diabetes and Metabolic Disorders Study Group. Prevalence of diabetes among men and women in China. N Engl J Med 2010; 362(12): 1090–1101

[4] Wang L, Gao P, Zhang M, Huang Z, Zhang D, Deng Q, Li Y, Zhao Z, Qin X, Jin D, Zhou M, Tang X, Hu Y, Wang L. Prevalence and ethnic pattern of diabetes and prediabetes in China in 2013. JAMA 2017; 317(24): 2515–2523

[5] Li Y, Teng D, Shi X, Qin G, Qin Y, Quan H, Shi B, Sun H, Ba J, Chen B, Du J, He L, Lai X, Li Y, Chi H, Liao E, Liu C, Liu L, Tang X, Tong N, Wang G, Zhang JA, Wang Y, Xue Y, Yan L, Yang J, Yang L, Yao Y, Ye Z, Zhang Q, Zhang L, Zhu J, Zhu M, Ning G, Mu Y, Zhao J, Teng W, Shan Z. Prevalence of diabetes recorded in mainland China using 2018 diagnostic criteria from the American Diabetes Association: national cross sectional study. BMJ 2020; 369: m997

[6] World Health Organization. Global action plan for the prevention and control of noncommunicable diseases 2013–2020. Geneva: World Health Organization. 2013. accessed April 26, 2021)

[7] United Nations. Sustainable development goals. 2015. accessed April 26, 2021)

[8] Meng Q, Mills A, Wang L, Han Q. What can we learn from China’s health system reform? BMJ 2019; 365: l2349

[9] Yuan B, Balabanova D, Gao J, Tang S, Guo Y. Strengthening public health services to achieve universal health coverage in China. BMJ 2019; 365: l2358

[10] Jia W, Weng J, Zhu D, Ji L, Lu J, Zhou Z, Zou D, Guo L, Ji Q, Chen L, Chen L, Dou J, Guo X, Kuang H, Li L, Li Q, Li X, Liu J, Ran X, Shi L, Song G, Xiao X, Yang L, Zhao Z; Chinese Diabetes Society. Standards of medical care for type 2 diabetes in China 2019. Diabetes Metab Res Rev 2019; 35(6): e3158

[11] American Diabetes Association. Comprehensive Medical Evaluation and Assessment of Comorbidities: Standards of Medical Care in Diabetes-2021. Diabetes Care 2021; 44(Suppl 1):S40–S52PMID: 33298415

[12] Cholesterol Treatment Trialists’ (CTT) Collaboration; Baigent C, Blackwell L, Emberson J, Holland LE, Reith C, Bhala N, Peto R, Barnes EH, Keech A, Simes J, Collins R. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials. Lancet 2010; 376(9753): 1670–1681

[13] Ji L, Hu D, Pan C, Weng J, Huo Y, Ma C, Mu Y, Hao C, Ji Q, Ran X, Su B, Zhuo H, Fox KA, Weber M, Zhang D; CCMR Advisory Board; CCMR-3B STUDY Investigators. Primacy of the 3B approach to control risk factors for cardiovascular disease in type 2 diabetes patients. Am J Med 2013; 126(10): 925.e11–925.e22

[14] Ruan Y, Yan QH, Xu JY, Yang QD, Yao HH, Li R, Shi Y. Epidemiology of diabetes in adults aged 35 and older from Shanghai, China. Biomed Environ Sci 2016; 29(6): 408–416

[15] Liu Y, Wu X, Cai C, Tang PY, Coufal MM, Qian Y, Luu SL, Fisher EB, Jia W. Peer support in Shanghai’s Commitment to diabetes and chronic disease self-management: program development, program expansion, and policy. Transl Behav Med 2020; 10(1): 13–24

[16] Scanlon PH, Malhotra R, Greenwood RH, Aldington SJ, Foy C, Flatman M, Downes S. Comparison of two reference standards in validating two field mydriatic digital photography as a method of screening for diabetic retinopathy. Br J Ophthalmol 2003; 87(10): 1258–1263

[17] World Health Organization. Prevention of blindness from diabetes mellitus: report of a WHO consultation in Geneva, Switzerland. 2006. accessed March 10, 2020)

[18] Writing Group of 2018 Chinese Guidelines for the Management of Hypertension, Chinese Hypertension League, Chinese Society of Cardiology, Chinese Medical Doctor Association Hypertension Committee, Hypertension Branch of China International Exchange and Promotive Association for Medical and Health Care, Hypertension Branch of Chinese Geriatric Medical Association. 2018 Chinese guidelines for the management of hypertension.. Chin J Cardiovas Med 2019; 24: 24–56

[19] Bao Y, Lu J, Wang C, Yang M, Li H, Zhang X, Zhu J, Lu H, Jia W, Xiang K. Optimal waist circumference cutoffs for abdominal obesity in Chinese. Atherosclerosis 2008; 201(2): 378–384

[20] Wong TY, Sun J, Kawasaki R, Ruamviboonsuk P, Gupta N, Lansingh VC, Maia M, Mathenge W, Moreker S, Muqit MMK, Resnikoff S, Verdaguer J, Zhao P, Ferris F, Aiello LP, Taylor HR. Guidelines on diabetic eye care: the International Council of Ophthalmology Recommendations for Screening, Follow-up, Referral, and Treatment Based on Resource Settings. Ophthalmology 2018; 125(10): 1608–1622

[21] Wilson PW, D’Agostino RB, Parise H, Sullivan L, Meigs JB. Metabolic syndrome as a precursor of cardiovascular disease and type 2 diabetes mellitus. Circulation 2005; 112(20): 3066–3072

[22] Kanaya AM, Adler N, Moffet HH, Liu J, Schillinger D, Adams A, Ahmed AT, Karter AJ. Heterogeneity of diabetes outcomes among asians and pacific islanders in the US: the diabetes study of northern california (DISTANCE). Diabetes Care 2011; 34(4): 930–937

[23] Selvin E, Steffes MW, Zhu H, Matsushita K, Wagenknecht L, Pankow J, Coresh J, Brancati FL. Glycated hemoglobin, diabetes, and cardiovascular risk in nondiabetic adults. N Engl J Med 2010; 362(9): 800–811

[24] Kosiborod M, Gomes MB, Nicolucci A, Pocock S, Rathmann W, Shestakova MV, Watada H, Shimomura I, Chen H, Cid-Ruzafa J, Fenici P, Hammar N, Surmont F, Tang F, Khunti K; DISCOVER investigators. Vascular complications in patients with type 2 diabetes: prevalence and associated factors in 38 countries (the DISCOVER study program). Cardiovasc Diabetol 2018; 17(1): 150

[25] Rawshani A, Rawshani A, Franzén S, Eliasson B, Svensson AM, Miftaraj M, McGuire DK, Sattar N, Rosengren A, Gudbjörnsdottir S. Mortality and cardiovascular disease in type 1 and type 2 diabetes. N Engl J Med 2017; 376(15): 1407–1418

[26] Gaede P, Vedel P, Larsen N, Jensen GV, Parving HH, Pedersen O. Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes. N Engl J Med 2003; 348(5): 383–393

[27] Gaede P, Lund-Andersen H, Parving HH, Pedersen O. Effect of a multifactorial intervention on mortality in type 2 diabetes. N Engl J Med 2008; 358(6): 580–591

[28] Bakke Å, Tran AT, Dalen I, Cooper JG, Løvaas KF, Jenum AK, Berg TJ, Madsen TV, Nøkleby K, Gjelsvik B, Claudi T, Skeie S, Carlsen S, Sandberg S, Thue G. Population, general practitioner and practice characteristics are associated with screening procedures for microvascular complications in type 2 diabetes care in Norway. Diabet Med 2019; 36(11): 1431–1443

[29] Seo DH, Kang S, Lee YH, Ha JY, Park JS, Lee BW, Kang ES, Ahn CW, Cha BS. Current management of type 2 diabetes mellitus in primary care clinics in Korea. Endocrinol Metab (Seoul) 2019; 34(3): 282–290

[30] Ali MK, Bullard KM, Saaddine JB, Cowie CC, Imperatore G, Gregg EW. Achievement of goals in U.S. diabetes care, 1999−2010. N Engl J Med 2013; 368(17): 1613–1624

[31] Stone MA, Charpentier G, Doggen K, Kuss O, Lindblad U, Kellner C, Nolan J, Pazderska A, Rutten G, Trento M, Khunti K; GUIDANCE Study Group. Quality of care of people with type 2 diabetes in eight European countries: findings from the Guideline Adherence to Enhance Care (GUIDANCE) study. Diabetes Care 2013; 36(9): 2628–2638

[32] Luk AOY, Hui EMT, Sin MC, Yeung CY, Chow WS, Ho AYY, Hung HF, Kan E, Ng CM, So WY, Yeung CK, Chan KS, Chan KW, Chan PF, Siu SC, Tiu SC, Yeung VTF, Chan JCN, Chan FWK, Cheung C, Cheung NT, Ho ST, Lam KSL, Yu LWL, Chao D, Lau IT. Declining trends of cardiovascular-renal complications and mortality in type 2 diabetes: the Hong Kong Diabetes Database. Diabetes Care 2017; 40(7): 928–935

[33] De Cosmo S, Viazzi F, Pacilli A, Giorda C, Ceriello A, Gentile S, Russo G, Rossi MC, Nicolucci A, Guida P, Di Bartolo P, Pontremoli R; AMD-Annals Study Group. Achievement of therapeutic targets in patients with diabetes and chronic kidney disease: insights from the Associazione Medici Diabetologi Annals initiative. Nephrol Dial Transplant 2015; 30(9): 1526–1533

[34] Kar D, Gillies C, Zaccardi F, Webb D, Seidu S, Tesfaye S, Davies M, Khunti K. Relationship of cardiometabolic parameters in non-smokers, current smokers, and quitters in diabetes: a systematic review and meta-analysis. Cardiovasc Diabetol 2016; 15(1): 158

[35] Alomari MA, Khabour OF, Alzoubi KH, Shqair DM, Eissenberg T. Central and peripheral cardiovascular changes immediately after waterpipe smoking. Inhal Toxicol 2014; 26(10): 579–587

[36] Cryer PE, Haymond MW, Santiago JV, Shah SD. Norepinephrine and epinephrine release and adrenergic mediation of smoking-associated hemodynamic and metabolic events. N Engl J Med 1976; 295(11): 573–577

[37] Narkiewicz K, van de Borne PJ, Hausberg M, Cooley RL, Winniford MD, Davison DE, Somers VK. Cigarette smoking increases sympathetic outflow in humans. Circulation 1998; 98(6): 528–534

[38] Waeber B, Schaller MD, Nussberger J, Bussien JP, Hofbauer KG, Brunner HR. Skin blood flow and cigarette smoking: the role of vasopressin. Clin Exp Hypertens A 1984; 6(10-11): 2003–2006

[39] Li G, Wang H, Wang K, Wang W, Dong F, Qian Y, Gong H, Hui C, Xu G, Li Y, Pan L, Zhang B, Shan G. The association between smoking and blood pressure in men: a cross-sectional study. BMC Public Health 2017; 17(1): 797

[40] Gordon T, Kannel WB, Dawber TR, McGee D. Changes associated with quitting cigarette smoking: the Framingham Study. Am Heart J 1975; 90(3): 322–328

[41] Green MS, Harari G. A prospective study of the effects of changes in smoking habits on blood count, serum lipids and lipoproteins, body weight and blood pressure in occupationally active men. The Israeli CORDIS Study. J Clin Epidemiol 1995; 48(9): 1159–1166

[42] Seltzer CC. Effect of smoking on blood pressure. Am Heart J 1974; 87(5): 558–564

[43] Lee DH, Ha MH, Kim JR, Jacobs DR Jr. Effects of smoking cessation on changes in blood pressure and incidence of hypertension: a 4-year follow-up study. Hypertension 2001; 37(2): 194–198

[44] Rawshani A, Rawshani A, Franzén S, Sattar N, Eliasson B, Svensson AM, Zethelius B, Miftaraj M, McGuire DK, Rosengren A, Gudbjörnsdottir S. Risk factors, mortality, and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med 2018; 379(7): 633–644

[45] Fagard RH. Smoking amplifies cardiovascular risk in patients with hypertension and diabetes. Diabetes Care 2009; 32 (Suppl 2): S429–S431PMID: 19875595

RIGHTS & PERMISSIONS

Higher Education Press